BZBulat A. Ziganshin

Bulat A. Ziganshin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bulat A. Ziganshin has a total of 252 co-authors. Here are the top co-authors by number of shared publications:

  • John Augoustides

    Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT 06510, USA

    102 shared publications
  • Mohammad A. Zafar

    Yale School of Medicine Department of Surgery, Aortic Institute at Yale-New Haven, New Haven, USA

    17 shared publications
  • Mohammad A. Zafar

    Aortic Institute at Yale-New Haven, Yale University School of Medicine, New Haven, Connecticut

    4 shared publications
  • Ayman Saeyeldin

    Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut

    3 shared publications
  • Dimitra Papanikolaou

    Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, USA

    3 shared publications
  • John A. Rizzo

    Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut

    3 shared publications

Latest Publications

  • Top Cited Papers

    Thoracic aortic aneurysm

    by Tim Berger, Julia Dumfarth, Maximilian Kreibich, Kenji Minatoya, Bulat A. Ziganshin, Martin Czerny

    Aortic medicine has undergone remarkable progress in recent decades with regard to our understanding and treatment of aortic disease. In the past decade, the scientific community has called for the aorta to be viewed as an independent organ, advocating for a holistic approach to understanding thoracic aortic disease, integrating its embryological development, wall composition, pathophysiological mechanisms, surveillance and treatment. Thoracic aortic aneurysm (TAA) is a potentially fatal disease characterized by abnormal dilation of the thoracic aorta, whereby the structural integrity of the vessel wall is compromised. Although epidemiological studies of TAA are confounded by its asymptomatic nature and diagnostic challenges, available evidence suggests that TAA prevalence and treatment outcomes vary according to race, sex and socioeconomic factors. Pathophysiological mechanisms involve interactions between vascular smooth muscle cells and the extracellular matrix, influenced by genetic predisposition and embryological factors as well as arterial hypertension. Diagnosis relies on advanced imaging techniques, with CT angiography considered to be the gold standard diagnostic tool and with genetic screening recommended for heritable conditions. Preventive measures focus on managing cardiovascular risk factors, whereas treatment includes medical management, as well as endovascular and open surgical repair. TAA has a major effect on quality of life, particularly in younger, female and genetically predisposed patients, necessitating further research and tailored interventions.


  • Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials

    by Lokman H. Tanriverdi, Annie Barrett, Asanish Kalyanasundaram, Mohammad A. Zafar, Bulat A. Ziganshin, John A. Elefteriades


  • Open Access

    Genetic Overlap of Thoracic Aortic Aneurysms and Intracranial Aneurysms

    by Mah I Kan Changez, Afsheen Nasir, Alexandra Sonsino, Syeda Manahil Jeoffrey, Asanish Kalyanasundaram, Mohammad A. Zafar, Bulat A. Ziganshin, John A. Elefteriades

    Objective: Thoracic aortic aneurysms (TAAs) and intracranial aneurysms (ICAs) share overlapping genetic and pathophysiological mechanisms, yet the genetic interplay between these conditions remains insufficiently explored. This study aimed to identify common genetic factors underlying TAA and ICA. Methods: A comprehensive review of genome-wide association studies (GWASs) and retrospective clinical studies was conducted using PubMed, Orbis, and Web of Science. Articles addressing the genetic etiologies of TAA and ICA were analyzed. Separate lists of causative genes were compiled, and commonalities were identified. A Venn diagram was constructed to illustrate genetic overlap and shared physiological pathways. Results: We identified 24 overlapping genes associated with TAA and ICA, including LTBP2, TGFB2, TGFB3, TGFBR1, TGFBR2, SMAD2, SMAD3, COL1A2, COL3A1, COL4A1, COL5A1, COL5A2, FBN1, FBN2, ELN, LOX ACTA2, MYH11, MYLK, ABCC6, NOTCH1, MED12, PKD1, and PKD2. These genes are involved in pathways related to connective tissue biology, contractile elements, extracellular matrix components, and transforming growth factor-β signaling. While vascular endothelium and cell cycle pathways were unique to ICA, TAA pathways predominantly involved extracellular matrix remodeling. Conclusions: This study highlights the significant genetic overlap between TAA and ICA, shedding light on shared molecular mechanisms. These findings underscore the importance of interdisciplinary awareness: neurologists, neurosurgeons, and neurointerventional radiologists should monitor ICA patients for potential TAA, while cardiologists, cardiac surgeons, vascular surgeons, and vascular interventionalists should consider ICA risks in TAA patients. Further research into these genetic pathways could enhance the understanding and management of both conditions.


  • Open Access

    Somatic Variants Acquired Later in Life Associated with Thoracic Aortic Aneurysms: JAK2 V617F

    by Christina Waldron, Mohammad A. Zafar, Deqiong Ma, Hui Zhang, Daniel Dykas, Bulat A. Ziganshin, Andreea Popa, Alokkumar Jha, Jennifer M. Kwan, John A. Elefteriades

    The JAK2 V617F somatic variant is a well-known driver of myeloproliferative neoplasms (MPN) associated with an increased risk for athero-thrombotic cardiovascular disease. Recent studies have demonstrated its role in the development of thoracic aortic aneurysm (TAA). However, limited clinical information and level of JAK2 V617F burden have been provided for a comprehensive evaluation of potential confounders. A retrospective genotype-first study was conducted to identify carriers of the JAK2 V617F variant from an internal exome sequencing database in Yale DNA Diagnostics Lab. Additionally, the overall incidence of somatic variants in the JAK2 gene across various tissue types in the healthy population was carried out based on reanalysis of SomaMutDB and data from the UK Biobank (UKBB) cohort to compare our dataset to the population prevalence of the variant. In our database of 12,439 exomes, 594 (4.8%) were found to have a thoracic aortic aneurysm (TAA), and 12 (0.049%) were found to have a JAK2 V617F variant. Among the 12 JAK2 V617F variant carriers, five had a TAA (42%), among whom four had an ascending TAA and one had a descending TAA, with a variant allele fraction ranging from 11.2% to 20%. Among these five patients, 60% were female, and average age at diagnosis was 70 (49–79). The mean ascending aneurysm size was 5.05 cm (range 4.6–5.5 cm), and four patients had undergone surgical aortic replacement or repair. UKBB data revealed a positive correlation between the JAK2 V617F somatic variant and aortic valve disease (effect size 0.0086, p = 0.85) and TAA (effect size = 0.004, p = 0.92), although not statistically significant. An unexpectedly high prevalence of TAA in our dataset (5/594, 0.84%) is greater than the prevalence reported before for the general population, supporting its association with TAA. JAK2 V617F may contribute a meaningful proportion of otherwise unexplained aneurysm patients. Additionally, it may imply a potential JAK2-specific disease mechanism in the developmental of TAA, which suggests a possible target of therapy that warrants further investigation.


  • Open Access

    Evidence Accumulates: Patients with Ascending Aneurysms Are Strongly Protected from Atherosclerotic Disease

    by Christina Waldron, Mohammad A. Zafar, Bulat A. Ziganshin, Gabe Weininger, Nimrat Grewal, John A. Elefteriades

    Ascending thoracic aortic aneurysms may be fatal upon rupture or dissection and remain a leading cause of death in the developed world. Understanding the pathophysiology of the development of ascending thoracic aortic aneurysms may help reduce the morbidity and mortality of this disease. In this review, we will discuss our current understanding of the protective relationship between ascending thoracic aortic aneurysms and the development of atherosclerosis, including decreased carotid intima–media thickness, low-density lipoprotein levels, coronary and aortic calcification, and incidence of myocardial infarction. We also propose several possible mechanisms driving this relationship, including matrix metalloproteinase proteins and transforming growth factor-β.


  • Open Access

    Nonsize Criteria for Surgical Intervention on the Ascending Thoracic Aorta

    by John A. Elefteriades, Bulat A. Ziganshin, Mohammad A. Zafar

    For decades, aortic surgery has relied on size criteria for intervention on the ascending aorta. While diameter has served well, diameter alone falls short of an ideal criterion. Herein, we examine the potential application of other, nondiameter criteria in aortic decision-making. These findings are summarized in this review. We have conducted multiple investigations of specific alternate nonsize criteria by leveraging our extensive database, which includes complete, verified anatomic, clinical, and mortality data on 2,501 patients with thoracic aortic aneurysm (TAA) and dissections (198 Type A, 201 Type B, and 2102 TAAs). We examined 14 potential intervention criteria. Each substudy had its own specific methodology, reported individually in the literature. The overall findings of these studies are presented here, with a special emphasis on how the findings can be incorporated into enhanced aortic decision-making—above and beyond sheer diameter. The following nondiameter criteria have been found useful in decision-making regarding surgical intervention. (1) Pain: In the absence of other specific cause, substernal chest pain mandates surgery. Well-developed afferent neural pathways carry warning signals to the brain. (2) Aortic length/tortuosity: Length is emerging as a mildly better predictor of impending events than diameter. (3) Genes: Specific genetic aberrations provide a powerful predictor of aortic behavior; malignant genetic variants obligate earlier surgery. (4) Family history: Aortic events closely follow those in relatives with a threefold increase in likelihood of aortic dissection for other family members once an index family dissection has occurred. (5) Bicuspid aortic valve: Previously thought to increase aortic risk (as a “Marfan light” situation), current data show that bicuspid valve is not a predictor of higher risk. (6) Diabetes actually protects against aortic events, via mural thickening and fibrosis. (7) Biomarkers: A specialized “RNA signature test” identifies aneurysm-bearing patients in the general population and promises to predict impending dissection. (8) Aortic stress: Blood pressure (BP) elevation from anxiety/exertion precipitates dissection, especially with high-intensity weightlifting. (9) Root dilatation imposes higher dissection risk than supracoronary ascending aneurysm. (10) Inflammation on positron emission tomography (PET) imaging implies high rupture risk and merits surgical intervention. (11) A KIF6 p.Trp719Arg variant elevates aortic dissection risk nearly two-fold. (12) Female sex confers some increased risk, which can be largely accommodated by using body-size-based nomograms (especially height nomograms). (13) Fluoroquinolones predispose to catastrophic dissection events and should be avoided rigorously in aneurysm patients. (14) Advancing age makes the aorta more vulnerable, increasing likelihood of dissection. In conclusion, nondiameter criteria can beneficially be brought to bear on the decision to observe or operate on specific TAA.


  • Open Access

    KIF6 Trp719Arg Genetic Variant Increases Risk for Thoracic Aortic Dissection

    by Juan J. Velasco, Yupeng Li, Bulat A. Ziganshin, Mohammad A. Zafar, John A. Rizzo, Deqiong Ma, Hui Zang, Asanish Kalyanasundaram, John A. Elefteriades

    Background: KIF6 (kinesin family member 6), a protein coded by the KIF6 gene, serves an important intracellular function to transport organelles along microtubules. In a pilot study, we found that a common KIF6 Trp719Arg variant increased the propensity of thoracic aortic aneurysms (TAA) to suffer dissection (AD). The present study aims for a definite investigation of the predictive ability of KIF6 719Arg vis à vis AD. Confirmatory findings would enhance natural history prediction in TAA. Methods: 1108 subjects (899 aneurysm and 209 dissection patients) had KIF6 719Arg variant status determined. Results: The 719Arg variant in the KIF6 gene correlated strongly with occurrence of AD. Specifically, KIF6 719Arg positivity (homozygous or heterozygous) was substantially more common in dissectors (69.8%) than non-dissectors (58.5%) (p = 0.003). Odds ratios (OR) for suffering aortic dissection ranged from 1.77 to 1.94 for Arg carriers in various dissection categories. These high OR associations were noted for both ascending and descending aneurysms and for homozygous and heterozygous Arg variant patients. The rate of aortic dissection over time was significantly higher for carriers of the Arg allele (p = 0.004). Additionally, Arg allele carriers were more likely to reach the combined endpoint of dissection or death (p = 0.03). Conclusions: We demonstrate the marked adverse impact of the 719Arg variant of the KIF6 gene on the likelihood that a TAA patient will suffer aortic dissection. Clinical assessment of the variant status of this molecularly important gene may provide a valuable “non-size” criterion to enhance surgical decision making above and beyond the currently used metric of aortic size (diameter).


  • Table of contents

    by Xianbiao Xie, Xiao-Fu Dai, Guanhua Fang, Zhihuang Qiu, De-Bin Jiang, Liangwan Chen, Vicente Orozco‐Sevilla, Joseph S. Coselli, John A. Elefteriades, Bulat A. Ziganshin, et al.

  • Open Access

    Celebrating 10 Years of AORTA

    by John A. Elefteriades, Bulat A. Ziganshin

    We are pleased to report that AORTA has now reached its 10-year anniversary. We wish to express appreciation to many individuals. We wish to thank especially our authors, who have submitted interesting and meaningful manuscripts for publication. These have reflected insight, imagination, and, very often, surgical courage. The accompanying collage ([Fig. 1]) represents just a fraction of the distinguished worldwide authorities who have published their work in AORTA. In 2021, we received manuscript submissions from 16 different countries (United States, United Kingdom, Turkey, Sweden, South Africa, Singapore, The Netherlands, Korea, Japan, Italy, Iran, India, Greece, Germany, Belgium, and Australia). We express appreciation to the Editorial Board for their varied and valued efforts. We express appreciation to our Reviewers, who have contributed immensely to enhancing submitted manuscripts toward increased scientific rigor and clarity. We thank Dr. Steven Korn and Science International Corporation for getting us started and leading us on the proper path. Our thanks go out to our current Publishers, the Thieme Group, with special appreciation for Graham Brumfield, Senior Executive Editor at Thieme Group for his leadership, and to Jessica Sieger, Editor and Project Manager for Thieme Group, who actually make things run. And, a special “thank you” goes out to our readers, who, as seen in the accompanying map ([Fig. 2]), literally span the globe. In 2020, AORTA had 12,652 full-text reads on tieme-connect.com. We would like to thank our sponsor Medtronic for supporting the Journal in 2021. We would like to thank Yale New Haven Hospital for generous and enduring support. Thank you all. We look forward to the next 10 years studying this amazing organ: the human aorta, which is “much more than a tube.”[1] Received: 17 February 2022 Accepted: 17 February 2022 Article published online: 31 May 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA